Management of pediatric choroidal neovascular membranes with intravitreal anti-VEGF agents: a retrospective consecutive case series
- 1 February 2011
- journal article
- case report
- Published by Elsevier BV in Canadian Journal of Ophthalmology
- Vol. 46 (1), 46-50
- https://doi.org/10.3129/i10-123
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndromePediatric Blood & Cancer, 2008
- Choroidal neovascularisation in childrenBritish Journal of Ophthalmology, 2008
- TREATMENT OF VASCULARLY ACTIVE FAMILIAL EXUDATIVE VITREORETINOPATHY WITH PEGAPTANIB SODIUM (MACUGEN)Retina, 2008
- Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group StudyJournal of Clinical Oncology, 2008
- Compassionate use of bevacizumab (Avastin®) in children and young adults with refractory or recurrent solid tumorsAnnals of Oncology, 2007
- INTRAVITREAL BEVACIZUMAB FOR THE MANAGEMENT OF CHOROIDAL NEOVASCULARIZATION IN PSEUDOXANTHOMA ELASTICUMRetina, 2007
- Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurityIndian Journal of Ophthalmology, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- The biology of VEGF and its receptorsNature Medicine, 2003
- THE SURGICAL REMOVAL OF SUBFOVEAL CHOROIDAL NEOVASCULARIZATIONRetina, 1996